ASX News
Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging
Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging product
Telix Pharmaceuticals Limited is pleased to announce it has entered into an exclusive distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of metastatic prostate cancer.
Under the terms of the agreement, IRE has been appointed as the exclusive commercial distributor of TLX591-CDx in France and French overseas territories, during both the initial period of ‘autorisation d’exploitation temporaire’ (temporary authorisation) and once full European marketing authorisation is granted in 2021.
TLX591-CDx does not have a marketing authorisation in any jurisdiction.
To read full media release please click here.
More Articles
Corporate Spotlight
Second Industry Body Updates Guidance for Use of PSMA PET Imaging
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 21 September 2021. Telix welcomes SNMMI updated Appropriate Use Criteria for PSMA PET...
Corporate Spotlight
Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer
16 September 2021 – Clinical Spotlight | Telix to support and participate in AdMeTech 5th Global Summit on Precision Diagnosis...
ASX News
NCCN Guidelines Updated to Include PSMA-PET Imaging
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes...
ASX News
FDA Approves Phase II Kidney Cancer Therapy Study
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix announces the FDA has accepted the IND Application to...
ASX News
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
Melbourne (Australia) and Bologna (Italy) – 13 September 2021. Telix enters a commercial distribution agreement with Radius for Telix’s prostate...
ASX News
Japanese Prostate Cancer Imaging Study Completes Enrolment
Melbourne (Australia) and Kyoto (Japan) – 9 September 2021. Telix has completed a Phase I clinical trial of TLX591-CDx for...
ASX News
Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics
Melbourne (Australia), Indianapolis (IN, U.S.A.), and Kettering (OH, U.S.A.) – 7 September 2021. Telix announces collaboration with Kettering Health on...
ASX News
Telix and Lightpoint Medical to Collaborate on Radioguided Surgery
Melbourne (Australia) – 23 August 2021. Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI®...
ASX News
Telix Half-Year Results 2021 and Company Update Conference Call
Melbourne (Australia) – 19 August 2021. Telix announces Half-Year Results 2021 and provides shareholder update
ASX News
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
Melbourne (Australia) – 19 August 2021. Telix releases details of two ancillary studies under the ProstACT program, including a Phase...
ASX News
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
Melbourne (Australia) – 18 August 2021. Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.
ASX News
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
Melbourne (Australia) – 18 August 2021. Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx...
ASX News
Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
Melbourne and Adelaide (Australia) – 17 August 2021. Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being...
ASX News
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
Melbourne (Australia) and London (United Kingdom) – 17 August 2021. Telix announces Phase II academic study of TLX66 in children...
ASX News
Telix H1 2021 Results and Company Update Conference Call
Melbourne (Australia) – 11 August 2021. Telix to hold investor conference call to present H1 2021 financial results and Company...
ASX News
First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
Melbourne (Australia) – 5 August 2021. Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study...
Corporate Spotlight
Ms. Helen Hovenga Joins Telix as Chief People Officer
4 August 2021 – Corporate Spotlight | Telix announces the appointment of Ms. Helen Hovenga in the role of Chief...
ASX News
Telix Seneffe Production Facility: Progress Update
Melbourne (Australia) and Seneffe (Belgium) – 30 July 2021. Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical...
ASX News
Activities Report and Appendix 4C for June 2021 Quarter
Melbourne (Australia) – 22 July 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June...
ASX News
ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update
Melbourne (Australia) – 20 July 2021. Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer...
Corporate Spotlight
Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA
19 July 2021 – Corporate Spotlight | Gabrielle Wermenbol joins Telix as Chief Financial Officer, Europe, Middle East & Africa...
Corporate Spotlight
Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations
Melbourne (Australia) – 12 July 2021. Telix announces that Ms. Kyahn Williamson has joined the Telix executive leadership team in...
ASX News
First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
Melbourne (Australia) – 23 June 2021. Telix announces that a first patient has been dosed in a Phase I study...
ASX News
IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update
Melbourne (Australia) – 21 June 2021. Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on...
ASX News
Telix Update on FDA New Drug Application Review for Illuccix®
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 17 June 2021. Telix announces participation in a late-cycle meeting with the U.S....
Corporate Spotlight
Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical...
Corporate Spotlight
Telix launches “Gallium Wave” Awareness Website
Melbourne (Australia) and Indianapolis (U.S.A.) – 11 June 2021. Telix announces the launch of a new website “Gallium Wave”, as...
Corporate Spotlight
Scott Law joins Telix as SVP Global Manufacturing Operations
11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations
ASX News
Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy
Liège (Belgium) and Gothenburg (Sweden) – 7 June 2021. Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of...